title: Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone?
authors.affiliation: aManson Unit, Médecins Sans Frontières, London, UK bDepartment of Infectious Diseases, Geelong Hospital, Geelong cDepartment of Medicine and Infectious Diseases, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia dMedical Unit, Médecins Sans Frontières, Geneva, Switzerland eCenter for Infectious Diseases Epidemiology Research, University of Cape Town, Cape Town, South Africa fDepartment of HIV, University Hospitals of Geneva, Geneva, Switzerland.
authors.forename: Daniel P
authors.initials: DP
authors.lastname: O'Brien
authors.forename: Eric
authors.initials: E
authors.lastname: Comte
authors.forename: Nathan
authors.initials: N
authors.lastname: Ford
authors.forename: Vanessa
authors.initials: V
authors.lastname: Christinet
authors.forename: Philipp
authors.initials: P
authors.lastname: du Cros
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D054312:Buruli Ulcer / Q000150:complications* / Q000188:drug therapy*; D004347:Drug Interactions; D024841:Fluoroquinolones; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D000077266:Moxifloxacin; D011804:Quinolines / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D044966:Anti-Retroviral Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin